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Purpose: To evaluate the inﬂuence of clinical and multimodal imaging parameters on the
duration of acute central serous chorioretinopathy (CSCR) episodes.
Methods: Consecutive patients with ﬁrst, treatment-naïve central serous chorioretinop-
athy episodes presenting within 20 days of symptoms onset were prospectively included.
They were reevaluated 15 days to 20 days later, followed by monthly evaluation for 6
months. Subfoveal choroidal thickness (SFCT), ﬂuorescein leakage intensity on ﬂuorescein
angiography, elevation of retinal pigment epithelium (RPE) lesions at leakage sites, focal/
multifocal pattern of indocyanine green angiography (ICGA) at baseline, time-dependent
pattern of subretinal ﬂuid (SRF) resorption on OCT using volume segmentation, history of
corticosteroid intake and mean blood pressure were evaluated using univariate (Log rank
test) and multivariate (Cox proportional hazard regression) survival analysis.
Results: Thirty-one patients were included (26 men, 5 women, mean age: 40.0 ± 8.9
years, range: 24–58), of which 26 (84%) had episode resolution by 6 months. Using uni-
variate analysis, episode duration was longer in cases with subfoveal choroidal thickness
$500 mm (P = 0.0002), retinal pigment epithelium elevation at leakage sites $50 mm (P =
0.033), and a peak in subretinal ﬂuid observed during follow-up (P = 0.013), and there was
a near-signiﬁcant association of intense ﬂuorescein leakage (P = 0.074) with longer epi-
sodes. Using multivariate analysis, subfoveal choroidal thickness $500 mm (P = 0.017),
retinal pigment epithelium elevation at leakage sites $50 mm (P = 0.010) and patient age
$40 years (P = 0.010) were signiﬁcantly and independently associated to longer episodes.
Indocyanine green angiography pattern, corticosteroid intake, and blood pressure did not
inﬂuence episode duration.
Conclusion: Older age, higher subfoveal choroidal thickness, and higher degree of
retinal pigment epithelium alteration at leakage sites are independent factors of longer
acute central serous chorioretinopathy episodes.
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Central serous chorioretinopathy (CSCR) is a cho-rioretinal disorder characterized by serous retinal
detachments frequently involving the macula and usu-
ally associated with focal pigment epithelial detach-
ments (PED), choroidal hyperpermeability, and
increased choroidal thickness. Acute CSCR classically
affects middle-aged working male individuals, whose
working ability may be compromised by the associated
visual burden. Because serous retinal detachments
resolve spontaneously within six months in most acute
CSCR episodes,1–3 observation without treatment is
generally recommended as initial management.4 For
cases with persistent serous retinal detachment or
severe vision loss, several treatment options are avail-
able. Photocoagulation of extramacular leaking points
by direct argon2,3 or micropulse laser5,6 can reduce the
duration of single episodes. Half-dose or half-ﬂuence
verteporﬁn photodynamic therapy (PDT) may contrib-
ute to shorten episode duration.7–12 Oral treatment by
mineralocorticoid-receptor (MR) antagonists has also
shown beneﬁcial effects.4,13–18 However, the ideal
timing for these different interventions still remains
to be determined. A better understanding of factors
inﬂuencing episode duration would help to detect
and treat earlier cases at risk for persistence, before
the development of photoreceptor and RPE damage
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because of long-lasting subretinal detachment.
Because choroidal vasodilation and leakage through
the RPE are key mechanisms leading to CSCR4 and
because most of subretinal ﬂuid resorption depends on
the pumping capacity of RPE cells, several features
involved in choroid/RPE physiology may inﬂuence
acute episode duration, among which subfoveal cho-
roidal thickness, elevation of PED, intensity of RPE
leakage and choroidal hyperpermeability, initial sub-
retinal ﬂuid volume, time-dependent ﬂuid resorption
pattern, patient age, history of steroid intake, and arte-
rial blood pressure. Although these factors can be ac-
cessed on routine clinical examination and retinal
imaging, their inﬂuence on episode duration has not
been previously investigated.
The aim of this study was to evaluate the inﬂuence of
these ocular and systemic factors on the duration and
resolution of ﬁrst, treatment-naïve, acute CSCR episodes.
Methods
Subjects
This observational, single-center, prospective study
was designed in accordance with the tenets of the
Declaration of Helsinki. Data collection and analysis
was approved by the Ethics Committee of the Swiss
Federal Department of Health (CER-VD no. 19/15). All
patients signed an informed consent. Consecutive
patients presenting at Jules-Gonin Eye Hospital
(Lausanne, Switzerland) with a ﬁrst episode of acute,
unilateral, and treatment-naive CSCR from January 1,
2014 to October 31, 2015 were included. A CSCR
episode was deﬁned as the association of visual
symptoms (vision impairment, metamorphopsia, mi-
cropsia, dyschromatopsia or central scotoma) in the
presence of subretinal ﬂuid on spectral-domain optical
coherence tomography (SD-OCT) with a leaking site on
ﬂuorescein angiography (FA) and choroidal vascular
hyperpermeability on indocyanine green angiography
(ICGA). Exclusion criteria were: initial presentation
later than 20 days after symptoms onset, follow-up
shorter than 6 months without resolution, spherical error
superior to 2 D, and presence of pigmentary changes on
fundoscopy or fundus autoﬂuorescence modiﬁcations
suggestive of previous CSCR episodes. The follow-up
scheme for this observational study included a second
visit within 10 days to 20 days of the baseline visit,
followed by repeated monthly clinical evaluation for 6
months. Ocular and medical history, including history of
corticosteroid intake, ocular examination, arterial blood
pressure measured at the initial visit, and the time from
symptoms onset (vision loss, metamorphopsia, microp-
sia, dyschromatopsia, or central scotoma) to the ﬁrst
visit, were recorded. Central serous chorioretinopathy
episode resolution was deﬁned as the complete reab-
sorption of subretinal ﬂuid (SRF) on SD-OCT images
acquired as described below. In case of nonresolution of
SRF at six months, a rescue therapy was proposed.
Laser photocoagulation was performed if the leaking
site was located more than 1,000 mm from the foveal
center. If laser was not possible, mineralocorticoid-
receptor antagonist therapy by oral eplerenone (25 mg
daily) or spironolactone (25 mg daily) was administered
in the absence of contraindications, and otherwise pho-
todynamic therapy was used.
Retinal Imaging
Imaging was performed after standard pupillary
dilation using tropicamide 0.5% drops with the Spec-
tralis (Heidelberg Engineering, Heidelberg, Germany).
At all visits, a 20° · 20° 97-sections SD-OCT macular
volume, a 30° enhanced-depth imaging (EDI) SD-OCT
horizontal scan through the fovea the “automatic real
time” averaging set at the maximal value of 100 images,
a 30° · 30° fundus infrared reﬂectance, and a 30° · 30°
fundus autoﬂuorescence were acquired. Fluorescein
angiography and green indocyanine-green angiography
were performed at the baseline visit.
For each case, the site of maximum ﬂuorescein
leakage on FA was identiﬁed by one observer (FBC).
The height of pigment epithelial defects at these sites,
consisting in PED or RPE bumps, was measured by
a single observer (AD) using the built-in Spectralis
software (Heidelberg Eye Explorer, version 1.9.10.0).
Elevation was deﬁned as 0 mm when no RPE lesion
associated with the leakage site was observed.
The subfoveal choroidal thickness (SFCT) was
measured by the same observer on baseline
enhanced-depth imaging scans as the axial distance
from the RPE to the outer choroid/sclera interface. In
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cases where the interface was ambiguous, the senior
author (FBC) determined the SFCT. The maximal
height of subretinal detachment was measured simi-
larly as the axial distance between the RPE and the
outer aspect of photoreceptor outer segments.
The macular volume was automatically measured by
the software over an Early Treatment Diabetic Reti-
nopathy Study (ETDRS) grid centered on the macula.
Multifocal choroidal hyperpermeability was deﬁned
as the presence of several hypercyanescent areas on
midphase indocyanine-green angiography (10–12 mi-
nutes after dye injection).
Fluorescein Expansion Ratio
The intensity of leakage at the previously identiﬁed
leakage sites on FA was estimated by quantifying the
relative expansion of hyperﬂuorescence from early
phase (40–60 seconds) to midphase (2–2.5 minutes).
Angiograms were exported as TIFF ﬁles and were
processed on Matlab using a semiautomated custom
algorithm adapted from the method described by Pryds
et al.19 The leakage site was indicated manually, and
the borders of the hyperﬂuorescent area were automat-
ically detected using the grayscale intensity threshold
of 0.75 · Imax, where Imax is the maximal ﬂuores-
cence intensity at the leakage site. The ratio between
hyperﬂuorescent areas at midphase and early phase
was calculated to provide the ﬂuorescein leakage ratio.
Subretinal Fluid Volume
The volume of subretinal ﬂuid was calculated at each
timepoint using a custom-built algorithm on Matlab
(version 2015b; Mathworks, Natick, MA). Brieﬂy, the
97 SD-OCT scans corresponding to the macular volume
were exported as PNG ﬁles, and the borders of the
serous retinal detachment were segmented on each scan
using an intensity-based method. After visual veriﬁca-
tion of the segmentation, the volume was obtained
by trapezoidal integration, and a heat map of the
subretinal detachment was generated. The kinetics of
SRF resorption was then analyzed in each patient by
comparing SRF volumes at each timepoint.
Statistical Analyses
Survival analyses were performed using the
R software (version 3.1.3; R Foundation for Statistical
Computing, R Core Team, 2015, Vienna, Austria.
Fig. 1. Survival curve showing the time-dependent resolution rate of 31
acute episodes of central serous chorioretinopathy from the time of the
initial visit. All patients presented within 20 days after onset of symp-
toms. By 6 months, resolution was observed in 26 patients. The 95%
conﬁdence interval is colored in gray.
Table 1. Clinical and Imaging Characteristics of 31
Patients With a First Episode of Acute, Treatment-Naive
Central Serous Chorioretinopathy
Subjects (male/female), N 31 (26/5)
Age, years 40.0 ± 8.9 (24.3–58.3)
Cases with CSCR episode
resolution by 6 months,
N (%)
26 (83.9)
Time to CSCR episode
resolution, days
83 ± 46 (21–180)
Time from symptoms onset
to ﬁrst visit, days
9.0 ± 6.2 (0–20)
Type of RPE lesion at
leakage sites, N (%)
PED 13 (41.9)
REP bump 14 (45.2)
No lesion 4 (12.9)
RPE elevation at leakage
sites, mm
58.1 ± 53.3 (0–279)
Subfoveal choroidal
thickness, mm
479.9 ± 82.2 (302–619)
Fluorescein expansion ratio
on FA
2.8 ± 2.1 (1.0–9.4)
Multifocal choroidal
hyperpermeability on
ICGA, N (%)
13 (41.9)
Initial SRF volume, mL 0.92 ± 0.95 (0.03–4.27)
Observation of a peak in
SRF volume, N (%)
13 (41.9)
Time from ﬁrst visit to SRF
peak observation, days
42.6 ± 18.2 (15–64)
Baseline visual acuity
logMAR (Snellen
equivalent)
0.10 ± 0.13 (0–0.53)
(20/25 [20/66–20/20])
Final visual acuity
logMAR (Snellen
equivalent)
0.03 ± 0.08 (0–0.30)
(20/21 [20/40–20/20])
Mean blood pressure, mmHg 110.9 ± 9.4 (92.5–136.5)
History of corticosteroid
intake, N (%)
11 (35.4)
Continuous values are reported as mean ± SD (range), where
appropriate.
CSCR, central serous chorioretinopathy; FA, ﬂuorescein angi-
ography; ICGA, indocyanine green angiography; logMAR, loga-
rithm of the minimal angle of resolution; RPE, retinal pigment
epithelium; SRF, subretinal ﬂuid.
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http://www.R-project.org/). The Kaplan–Meier method
with log-rank tests was used for univariate analyses,
and the Cox proportional hazard method for the multi-
variate analysis, with the “survival”20 package. Re-
sults were expressed in terms of hazard ratio and
adjusted hazard ratio, respectively. Parameters result-
ing in a P value #0.2 in the univariate analysis were
entered in the multivariate model, followed by step-
wise regression with the “MASS”21 package.
Survival curves were generated with the “ggplot”22
and “survminer” packages. For each investigated
parameter, a dichotomizing value was searched that
deﬁned 2 groups with a signiﬁcant difference in
episode resolution rate, under the condition that the
smallest group was formed by $11 patients (one-
third of the study population).
Agreement between segmentation of subretinal ﬂuid
volume, maximal subretinal ﬂuid height on SD-OCT,
and macular volume was estimated using Cohen’s
Kappa on R, with the “irr” package.23
Spearman correlation coefﬁcients were used to
investigate association between variables on GraphPad
Prism (version 5.0f; GraphPad Software, La Jolla,
CA). The logarithm of the minimal angle of resolution
(LogMAR) was used to calculate visual acuity means.
P values #0.05 were considered signiﬁcant.
Fig. 2. Spectrum of subfoveal
choroidal thickness in acute
central serous chorioretinop-
athy, visible on optical coher-
ence tomography scans (right)
passing through the fovea as
indicated by the green arrows
on infrared images (left): (A)
403 mm in a 37-year-old man,
(B) 469 mm in a 28-year-old
man, (C) 519 mm in a 38-year-
old man, and (D) 617 mm in
a 34-year-old-man.
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Results
Of 35 patients presenting with acute CSCR during
the study period, 31 fulﬁlled the inclusion criteria.
There were 26 men and 5 women, with a mean age
of 40.0 ± 8.9 years (median: 37.8 years, range: 24.3–
58.3 years). After 6 months of follow-up, CRSC
episodes were resolved in n = 26 patients (83.9%)
and persisted in n = 5 patients (16.1%). Among
resolved cases, the mean time from the initial visit
to resolution was 83 ± 46 days (median: 83 days,
range: 21–180 days). Four cases (12.9%) were
resolved after 1 month, 9 cases (29.0%) after 2
months, 16 cases (51.6%) after 3 months, 21 cases
(67.7%) after 4 months, and 23 cases (74.2%) after 5
months. A survival curve displaying the time-
dependent resolution rate of the 31 cases is dis-
played in Figure 1.
Fig. 3. Method to quantify
ﬂuorescein leakage expansion
on ﬂuorescein angiography
from early phase (40–60 sec-
onds) to midphase (2–2.5 mi-
nutes). A and B. Early phase
(A) and midphase (B) angio-
grams in a case with a very
weak leakage. The hyper-
ﬂuorescent area corresponding
to pixels whose intensity is
comprised within 75% of the
maximal hyperﬂuorescence is
indicated by a green outline.
The ﬂuorescein expansion ratio
was calculated as the ratio
between the hyperﬂuorescent
areas at midphase and early
phase and was 1.32. C and D.
Same method applied to early
phase (C) and midphase (D)
angiograms from a case with
intermediate ink-blot leakage
pattern, yielding a ﬂuorescein
expansion ratio of 3.98. E and
F. Same method applied to
early (E) and midphase (F) an-
giograms from a case with
intense smokestack leakage
pattern, yielding a ﬂuorescein
expansion ratio of 6.01.
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Clinical and imaging characteristics are summarized
in Table 1. Subfoveal choroidal thickness ranged from
302 mm to 619 mm (mean: 479.9 mm) (Figure 2), the
ﬂuorescein expansion ratio ranged from 1.0 to 9.4
(mean: 2.8) (Figure 3), 13 patients had a PED, 14
had a RPE bump, and 4 had no RPE lesion at the
leakage site, and the corresponding RPE elevation
ranged from 0 mm to 279 mm (mean: 58.1 mm)
(Figure 4). When analyzing the kinetics of subretinal
ﬂuid resorption using serial SRF volume segmentation
on SD-OCT, a peak in SRF volume (higher than the
initial value) was observed in n = 13 subjects during
follow-up (Figure 5), while n = 18 subjects presented
a progressive decrease in SRF volume from the initial
visit (Figure 6). The mean time from the ﬁrst visit to
observed SRF volume peak was 42.6 days. A peak in
macular volume on SD-OCT was also detected at the
same timepoints in these subjects (kappa = 1.0, P ,
0.0001), but there was only a moderate agreement in
peak detection between subretinal ﬂuid volume and
maximal height of subretinal detachment on
SD-OCT (kappa = 0.49, P = 0.0013).
Using univariate survival analysis, the duration of
CSCR episodes was longer in patients with SFCT
$500 mm (P = 0.0002), those with RPE elevation at
leakage sites higher than 50 mm (P = 0.033) and
those with a peak in subretinal ﬂuid observed dur-
ing follow-up (P = 0.013). There was a near-
signiﬁcant association of intense ﬂuorescein leakage
(ﬂuorescein expansion ratio $ 2) with longer epi-
sodes (P = 0.074). In contrast, patient age (P =
0.18), initial subretinal ﬂuid volume (P = 0.12),
Fig. 4. Optical coherence
tomography of pigment epithe-
lial lesions (right) at leaking sites
on ﬂuorescein angiograms (left)
in acute central serous chorior-
etinopathy. A and B. Pigment
epithelial bumps (yellow arrows)
with estimated height of 25 mm
in a 36-year-old man (A) and
41mm in a 28-year-old man (B).
C and D. Pigment epithelial de-
tachments (yellow arrows) with
estimated height of 54 mm in
a 39-year-old man(C) and 163
mm in a 52-year-old woman (D).
1910 RETINA, THE JOURNAL OF RETINAL AND VITREOUS DISEASES  2017  VOLUME 37  NUMBER 10
focal/multifocal pattern of choroidal hyperperme-
ability on indocyanine-green angiography (P =
0.63), history of corticosteroid intake (P = 0.98), or
mean arterial blood pressure (P = 0.67) did not have
a signiﬁcant effect on episode durations.
Variables with a signiﬁcance level #0.2 were
selected for the Cox multivariate survival model, with
the assumption of proportional hazard. After stepwise
multivariate regression, SFCT ($500 mm, P = 0.017),
RPE elevation at leakage sites ($50 mm, P = 0.010),
and patient age ($40 years, P = 0.010) remained inde-
pendent signiﬁcant contributors to longer duration of
CSCR episodes. Comparative survival curves are dis-
played in Figures 7 and 8 and detailed survival results
are reported in Table 2.
To conﬁrm the robustness of these ﬁndings, we
repeated the same analyses with the time from
symptoms onset (as reported by the patient), instead
of the time from the ﬁrst visit. This modiﬁcation did
not affect the results nor the signiﬁcance levels in both
the univariate and multivariate analyses.
To understand differences between univariate and
multivariate results, we investigated possible corre-
lations between variables. There were signiﬁcant
correlations between initial subretinal ﬂuid volume
and SFCT (r = 0.36, P = 0.046); between observation
of a peak in subretinal ﬂuid and SFCT (r = 0.45, P =
0.010); between the ﬂuorescein expansion ratio and
the observation of a peak in subretinal ﬂuid (r = 0.39,
P = 0.036), the RPE elevation at leakage sites (r =
0.46, P = 0.026), and the initial subretinal ﬂuid vol-
ume (r = 0.58, P = 0.001). There was a near-
signiﬁcant trend between SFCT and ﬂuorescein
expansion ratio (r = 0.33, P = 0.082). There was also
a near-signiﬁcant, inverse correlation between
patient age and SFCT (r = 20.31, P = 0.09), pro-
viding a likely explanation for the nonsigniﬁcance of
age in the univariate analysis. However, both
Fig. 5. Follow-up of an acute episode of central serous chorioretinopathy in a 52-year-old woman using subretinal ﬂuid volume segmentation on optical
coherence tomography. There was an initial increase in subretinal ﬂuid from baseline (A–B) with a peak in subretinal ﬂuid volume at Day 35 (C) and
subsequent decrease (D–E) until subretinal ﬂuid resolution at Day 132 (not shown). Note the shape of a pigment epithelial detachment visible on the
segmented serous retinal detachment (same patient as Figure 4D).
Fig. 6. Follow-up of an acute
episode of central serous cho-
rioretinopathy in a 35-year-old
man using subretinal ﬂuid vol-
ume segmentation on optical
coherence tomography. No
increase in subretinal ﬂuid vol-
ume could be observed, with
a progressive decrease from
baseline (A) to all timepoints (B
and C) and resolution at Day 75
(not shown).
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parameters remained independent, consistently with
the results of the multivariate model.
Discussion
In acute CSCR, a serous retinal detachment of the
macula is generally not considered a threat for visual
function because visual acuity is not or mildly decreased
and recovers completely in most cases. But altered
quality of vision is a frequent complaint of patients
despite normal visual acuity levels and macular micro-
structure. Electrophysiology studies of acute CSCR
demonstrated that abnormal cone function observed
during an active episode persists after resoluton.24–27
Poorer recovery is associated with longer symptom
duration although the duration threshold before perma-
nent functional damage has not been clearly deter-
mined.28 This threshold would help to deﬁne the
optimal treatment timing for nonresolving cases.
In this study, we have analyzed the natural history
of acute, treatment-naive ﬁrst episodes of CSCR and
have correlated the duration of subretinal ﬂuid persis-
tence with clinically available parameters. We have
found that longer episode duration was independently
associated with higher SFCT, higher elevation of RPE
lesions at leakage sites, and older age.
Current hypotheses regarding the pathophysiology
of CSCR include choroidal vascular dilation manifest-
ing by choroidal thickening (or pachychoroid),29,30
possibly because of inappropriate activation of the
mineralocorticoid pathway,31,32 with concurrent RPE
alterations.33 However, the mechanisms involved in
SRF resolution or persistence are not fully understood.
Genetic studies of nonresolving CSCR cases have re-
ported an association with variants in the Complement
Factor H, ARMS 2 and Cadherin 5 genes,34–36 which
Fig. 7. Comparative survival curves showing the rate of subretinal detachment resolution over time about SFCT (A) and the height of RPE elevations at
leakage sites (B) on optical coherence tomography. The duration from initial visit to episode resolution was signiﬁcantly longer for subfoveal choroidal
thickness $500 mm (A) and pigment epithelium elevation $50 mm (B) both in the univariate and multivariate analyses. P-values from the univariate
(log-rank test) and the multivariate analysis (Cox proportional hazard model, between parenthesis) are reported.
Fig. 8. Comparative survival curves showing the rate of subretinal detachment resolution over time about the observation of a peak in SRF on optical
coherence tomography (A) and patient age (B). The duration from initial visit to episode resolution was signiﬁcantly longer for cases with an observed
peak in subretinal ﬂuid volume in the univariate analysis only (A). Episodes were also longer for patients aged 40 years or older in the multivariate
analysis only (B). P-values from the univariate (log-rank test) and the multivariate analysis (Cox proportional hazard model, between parenthesis) are
reported. ns, nonsigniﬁcant contributor to the multivariate model.
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are expressed by RPE cells.37–39 These ﬁndings sug-
gest that RPE changes contribute to the evolution
toward nonresolving CSCR. They are consistent with
previous ﬂuorescein angiography studies of CSCR40–42
demonstrating that SRF originates from an abnormal
passage from the choroid through the RPE, over-
whelming the pumping outﬂow capacity of RPE cells.
From this perspective, the association of longer episode
duration with higher SFCT and higher elevation of
RPE lesions at leakage sites are additional evidence
that the degree of choroidal and RPE dysfunction is
predictive of the ﬁnal outcome.
Another interesting ﬁnding is the association of
episode duration with older age. In aged human
maculae, RPE cells increase in size and lose their
regular hexagonal shape.43 Studies of aging primate
eyes have shown that mitochondrial elongation is
observed within RPE cells located of the macular area,
an indicator of increased metabolic stress.44 In aged
mouse eyes, RPE cells undergo multinucleation
because of aborted mitosis, one of the mechanisms
of cell death, and the contact with photoreceptor outer
segments inhibits RPE cell proliferation.45 Altogether,
these observations indicate that the repair capacity of
the RPE decreases with aging, particularly in the mac-
ula. This supports the notion that older age is associ-
ated with longer CSCR episodes, which may
ultimately contribute to the chronic epitheliopathy fre-
quently seen in older CSCR patients.46
We are unaware of previous reports relating the
time-course of acute CSCR episodes to clinical and
multimodal imaging features. In a study of 27 eyes
with acute CSCR performed before the OCT era, Klein
et al1 related the time-course of the disease to baseline
and ﬁnal ﬂuorescein angiography and repeated fundus
examinations. The mean time of resolution was 6
months after symptoms onset, with a maximal
observed duration of 12 months. More recently,
Pryds et al19 have investigated the ﬂuorescein leakage
rate based on early FA frames in cases with typical
smokestack leaks, using a method adapted in the
present study. They observed variable leakage rates,
a ﬁnding consistent with our results, but did not cor-
relate with other clinical characteristics. Yang et al47
have described the multimodal correlations between
RPE alterations including PED on SD-OCT, FA,
and indocyanine-green angiography in CSCR
patients but did not relate these ﬁndings to the dura-
tion of episodes.
The present study may have practical consequences
for the management of acute CSCR patients. Eighty-
four percent of consecutive patients demonstrated
spontaneous resolution of SRF within 6 months,
conﬁrming that observation for up to 6 months is
an appropriate initial management. However, patients
with SFCT $500 mm, PED with elevation $50 mm,
or age $ 40 years may be identiﬁed and warned of
a higher risk of longer CSCR duration, with a subse-
quent need for a longer follow-up and/or earlier treat-
ment decision. Although they were not independent
risk factors, observation of a peak in SRF during
follow-up and to a lesser extent an intense leakage
on the baseline FA may also contribute to identify
clinically patients at risk of longer episodes. Further
Table 2. Factors Inﬂuencing the Duration of Acute, Treatment-Naive, First CSCR Episodes by Univariate and Multivariate
Survival Analysis
Univariate* Multivariate†
HR (95% CI) P aHR (95% CI) P
Ocular factors
SFCT $ 500 mm 0.19 (0.08–0.46) 0.0002 0.29 (0.10–0.80) 0.017
RPE elevation at leakage site $50 mm 2.46 (1.07–5.65) 0.033 0.26 (0.09–0.73) 0.010
Peak in subretinal volume observed
during follow-up
0.35 (0.16–0.80) 0.013 — —
Initial serous retinal detachment
volume $1 mL
1.88 (0.85–4.16) 0.12 — —
Fluorescein leakage ratio $2 on FA 2.22 (0.93–5.31) 0.074 — —
Multifocal choroidal hyperpermeability on
midphase ICGA
0.82 (0.37–1.82) 0.63 — —
Systemic factors
Age $40 years 1.71 (0.78–3.74) 0.18 0.23 (0.07–0.70) 0.010
History of corticosteroid intake 0.99 (0.44–2.22) 0.98 — —
Mean arterial blood pressure $110 mmHg 1.19 (0.54–2.61) 0.67 — —
*Log-Rank statistics.
†Cox proportional hazard model followed by stepwise multivariate regression.
aHR, adjusted hazard ratio; CI, conﬁdence interval; FA, ﬂuorescein angiography; HR, hazard ratio; ICGA, indocyanine green
angiography; RPE, retinal pigment epithelium; SFCT, subfoveal choroidal thickness.
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studies are required to evaluate whether longer dura-
tions of macular serous detachment are associated
with worse vision quality and higher risks of CSCR
recurrence.
Limitations of this work include the size of the
study population because of its prospective nature
and the iterative subretinal ﬂuid follow-up that
prevented a continuous analysis of subretinal ﬂuid
evolution. As a result, peaks in subretinal ﬂuid
volume may have been missed, either between
follow-up timepoints, or before the initial visit. To
minimize this ﬂaw, we excluded patients presenting
more than 20 days after symptoms onset and
densiﬁed the initial follow-up schedule. In addition,
we did not consider recently described imaging signs
in CSCR such as hyporeﬂective subretinal lucency,48
loculation of ﬂuid in the posterior choroid,49 or pres-
ence of intraretinal hyperreﬂective foci.50 Finally,
SCFT were measured at a single time point at ﬁrst
visit and therefore diurnal variations of SFCT were
not considered.
To summarize, we have identiﬁed clinical param-
eters that are signiﬁcantly associated with longer
duration of ﬁrst acute CSCR episodes. Further
functional analyses are required to determine
whether these factors could help select patients
who should beneﬁt from earlier therapeutic inter-
ventions. These parameters could also be useful for
the design of future randomized studies of CSCR to
limit potential bias.
Key words: central serous chorioretinopathy, cho-
roid, retinal pigment epithelium, choroidal thickness,
optical coherence tomography, ﬂuorescein angiography,
indocyanine green angiography, age factors, time factors,
steroids.
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